Drug Type Antibody drug conjugate (ADC) |
Synonyms |
Target |
Mechanism HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists), MUC1 inhibitors(Mucin-1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 14 Apr 2023 |